Back to results
US 12,180,275 B2Granted
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
AssigneeProgastrine et Cancers S.À R.L.
InventorAlexandre Prieur
Life of this patent
Estimating the term…
Abstract
The present invention relates to combinations comprising anti-progastrin (anti-hPG) monoclonal antibodies and immune checkpoint inhibitors, as well as pharmaceutical compositions comprising said combinations. Methods of treatment of cancer using said combinations are also provided.
Claims19
A combination comprising:
- an anti-progastrin (anti-hPG) monoclonal antibody comprising:
- a heavy chain comprising CDR-H1, CDR-H2, and CDR-H3 of amino acid sequences SEQ ID NOs 28, 29, and 30, respectively, and
- a light chain comprising CDR-L1, CDR-L2, and CDR-L3 of amino acid sequences SEQ ID NOs 31, 32, and 33, respectively, and
- an immune checkpoint inhibitor, wherein said immune checkpoint inhibitor is an anti-PD1 antibody.
1 more element
A combination comprising:
- an anti-progastrin (anti-hPG) monoclonal antibody comprising:
- a heavy chain variable region of amino acid sequence selected between SEQ ID NO:69 and SEQ ID NO:71, and
- a light chain variable region of amino acid sequence selected between SEQ ID NO:
- 70 and SEQ ID NO:72, and
- an immune checkpoint inhibitor, wherein said immune checkpoint inhibitor is an anti-PD1 antibody.
2 more elements
Dependencies are inferred from the claim text.